Characteristics of CEBPAbi and non-CEBPAbi AML cohorts
| . | CEBPAbi (n = 14) . | Non-CEBPAbi (n = 401) . | P . |
|---|---|---|---|
| T-AML | 0 | 26 (6.5%) | — |
| Gender | |||
| Male | 9 (64.3%) | 226 (56.4%) | — |
| Female | 5 (35.7%) | 175 (43.6%) | — |
| Age (y) | |||
| Median | 54.5 | 58 | — |
| Range | 27-84 | 17-87 | — |
| WBC count (× 109/L) | |||
| Median | 88 | 31 | .04 |
| Range | 4-177 | 0.8-361.2 | — |
| Karyotype | |||
| Intermediate | 12 (85.7%) | 207 (51.6%) | .006 |
| NK | 7 (50%) | 125 (31.2%) | — |
| Non-intermediate | 2 (14.3%) | 192 (47.9) | — |
| Undetermined | 0 | 2 (0.5%) | — |
| FAB subtype | |||
| M0 | 0 | 27 (6.7%) | — |
| M1 | 8 (57.1%) | 107 (26.7%) | .03 |
| M2 | 3 (21.4%) | 49 (12.2%) | — |
| M3 | 0 | 15 (3.7%) | — |
| M4 | 0 | 57 (14.2%) | — |
| M5 | 0 | 66 (16.5%) | — |
| M6 | 0 | 10 (2.5%) | — |
| M7 | 0 | 3 (0.7%) | — |
| Not classifiable | 3 (21.4%) | 67 (16.7%) | — |
| Type of CEBPA mutation | |||
| Biallelic typical | 7 (50%) | — | — |
| Biallelic atypical | 7 (50%) | — | — |
| Monoallelic | — | 11 (2.7%) | — |
| . | CEBPAbi (n = 14) . | Non-CEBPAbi (n = 401) . | P . |
|---|---|---|---|
| T-AML | 0 | 26 (6.5%) | — |
| Gender | |||
| Male | 9 (64.3%) | 226 (56.4%) | — |
| Female | 5 (35.7%) | 175 (43.6%) | — |
| Age (y) | |||
| Median | 54.5 | 58 | — |
| Range | 27-84 | 17-87 | — |
| WBC count (× 109/L) | |||
| Median | 88 | 31 | .04 |
| Range | 4-177 | 0.8-361.2 | — |
| Karyotype | |||
| Intermediate | 12 (85.7%) | 207 (51.6%) | .006 |
| NK | 7 (50%) | 125 (31.2%) | — |
| Non-intermediate | 2 (14.3%) | 192 (47.9) | — |
| Undetermined | 0 | 2 (0.5%) | — |
| FAB subtype | |||
| M0 | 0 | 27 (6.7%) | — |
| M1 | 8 (57.1%) | 107 (26.7%) | .03 |
| M2 | 3 (21.4%) | 49 (12.2%) | — |
| M3 | 0 | 15 (3.7%) | — |
| M4 | 0 | 57 (14.2%) | — |
| M5 | 0 | 66 (16.5%) | — |
| M6 | 0 | 10 (2.5%) | — |
| M7 | 0 | 3 (0.7%) | — |
| Not classifiable | 3 (21.4%) | 67 (16.7%) | — |
| Type of CEBPA mutation | |||
| Biallelic typical | 7 (50%) | — | — |
| Biallelic atypical | 7 (50%) | — | — |
| Monoallelic | — | 11 (2.7%) | — |
Samples classified under “typical CEBPAbi” mutations have a combination of heterozygous N-terminal FS or nonsense and C-terminal in frame mutations. Other combinations are considered “atypical CEBPAbi.”
P values are based on 2-tailed Fisher’s exact test or Wilcoxon rank-sum test.
T-AML, therapy-related AML; WBC, white blood cell counts.